An open, self-control and multiple-center study to evaluate safety and efficacy of Protopic (0.1% tacrolimus) for vitiliginous patients

Trial Profile

An open, self-control and multiple-center study to evaluate safety and efficacy of Protopic (0.1% tacrolimus) for vitiliginous patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Apr 2016

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Vitiligo
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top